These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 15119994

  • 1. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ.
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus.
    Bhansali A, Masoodi SR.
    J Assoc Physicians India; 2005 May; 53():441-5. PubMed ID: 16124352
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metformin treatment and gastrointestinal symptoms in youth: Findings from a large tertiary care referral center.
    Meyers AG, Hudson J, Cravalho CKL, Matta ST, Villalobos-Perez A, Cogen F, Chung ST.
    Pediatr Diabetes; 2021 Mar; 22(2):182-191. PubMed ID: 33179823
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, Lu ZS, Sykes DM, Levetiracetam XR N01235 Study Group.
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [Abstract] [Full Text] [Related]

  • 9. [The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release].
    Kołodziejczyk MK, Kołodziejska J, Zgoda MM.
    Polim Med; 2012 Mar; 42(3-4):167-84. PubMed ID: 23457958
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes.
    Florez H, Luo J, Castillo-Florez S, Mitsi G, Hanna J, Tamariz L, Palacio A, Nagendran S, Hagan M.
    Postgrad Med; 2010 Mar; 122(2):112-20. PubMed ID: 20203462
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies.
    Fujioka K, Brazg RL, Raz I, Bruce S, Joyal S, Swanink R, Pans M.
    Diabetes Obes Metab; 2005 Jan; 7(1):28-39. PubMed ID: 15642073
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview.
    Schwartz SL, Gordi T, Hou E, Cramer M, Heritier M, Cowles VE.
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1235-43. PubMed ID: 18721117
    [Abstract] [Full Text] [Related]

  • 17. Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients.
    Guo L, Guo X, Li Y, Hong X, Jiang X, Su Q, Zhao D, Wu X, Ji L.
    Diabetes Metab Syndr; 2016 Sep; 10(3):137-42. PubMed ID: 26948203
    [Abstract] [Full Text] [Related]

  • 18. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS.
    Drug Des Devel Ther; 2015 Sep; 9():729-36. PubMed ID: 25678778
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.